FDA Extends CRADA with CluePoints

September 10, 2019

Applied Clinical Trials

The Federal Drug Administration has decided to extend the Cooperative Research and Development Agreement with CluePoints until October 2021. The extension will include research focused on real-world evidence and 'moderators of treatment effect'.

For more information, click here.

Related Content: